Effects of Allogenic Umbilical Cord-Derived Mesenchymal Stem Cells on Patients With Rotator Cuff Disease

Exclusion Criteria

• •Patients who have received subacromial injection therapy on the affected shoulder within the past 3 months.
• •Patients who have undergone rotator cuff surgery on the affected shoulder within the past 6 months
• •Patients with a history of receiving stem cell therapy for the shoulder.
• •Patients with the following shoulder conditions: complete rotator cuff tear, adhesive capsulitis, or isolated acromioclavicular joint arthropathy.
• •Patients showing or suspected of having the following radiological findings: malignancy, severe osteoarthritis of the glenohumeral joint, or skeletal abnormalities decreasing the subacromial space.
• •Patients presenting with symptomatic cervical spine disorders.
• •Patients with concurrent bilateral shoulder pain
• •Patients with polyarthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia.
• •Patients with neurological deficit
• •Pregnant women or lactating mothers.
• •Patients unwilling to use effective contraception during the clinical trial period.
• •Patients with current HBV, HCV, or HIV infections, or those with a positive RPR test.
• •Patients with severe diseases that may affect the clinical trial, including cardiovascular disease, renal disease, liver disease, endocrine disorders, or malignancies.
• •Patients who are unable to understand the questionnaires used for assessing their clinical status, including the Visual Analogue Scale (VAS), or those with psychiatric disorders impairing communication.
• •Patients who do not wish to participate in the clinical trial or are unable to comply with follow-up schedules.
• •Patients who have participated in another clinical trial within the last 3 months.
• •Patients deemed unsuitable for participation in this clinical trial at the investigator's discretion